The earnings call presented a strong commercial performance for FILSPARI, with significant growth in sales, positive clinical data, and international expansion efforts. However, challenges remain with potential generic competition for THIOLA and regulatory uncertainties for FILSPARI's approval in FSGS. Overall, the positive aspects, particularly around FILSPARI's performance and market potential, outweigh the challenges.

Company Guidance -

Q3 2025

In the Travere Therapeutics Second Quarter 2025 Financial Results Conference Call, the company provided guidance highlighting several key metrics and strategic advancements. FILSPARI, their leading treatment for IgA nephropathy, achieved approximately $72 million in net product sales in the U.S. during the second quarter, marking significant year-over-year growth and reinforcing its position as a foundational nephroprotective treatment. The quarter saw 745 new patient start forms, representing a 43% increase compared to the previous year, with a strong 70% of addressable patients having proteinuria levels below 1.5 grams per gram, further supporting FILSPARI's potential market expansion. Travere's focus on rare kidney diseases extends to their sNDA for FILSPARI's potential approval in FSGS, with a PDUFA date set for January 13, 2026. The company also reported an 82% increase in net product sales over the previous year, with a total revenue of $114.4 million, bolstered by a $17.5 million milestone payment from CSL Vifor. Additionally, Travere's financial position was strengthened with cash, cash equivalents, and marketable securities totaling $319.5 million as of June 30, 2025. The company anticipates further growth opportunities with their ongoing clinical programs and potential regulatory approvals.

Strong Commercial Performance of FILSPARI

FILSPARI net product sales reached approximately $72 million in the U.S. in the second quarter, representing significant year-over-year growth. This performance was driven by strong demand, expansion, and deepening of the prescriber base.

Expansion into FSGS Market

The sNDA review process for a potential second indication for FILSPARI in FSGS is advancing as expected, with a PDUFA date of January 13, 2026. If approved, FILSPARI would become the first ever treatment for this underserved patient community.

Positive Clinical Data for FILSPARI

In the Phase II SPARTAN trial, FILSPARI-treated patients achieved approximately a 70% proteinuria reduction, with nearly 60% reaching complete proteinuria remission and stable eGFR through 24 weeks.

Financial Growth

Net product sales grew approximately 82% over the same period last year, and total revenue for Q2 was $114.4 million.

International Expansion

Strong progress outside of the U.S. by partners, CSL Vifor and Renalis, to expand access to FILSPARI internationally.

Travere Therapeutics (TVTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TVTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.27 / -	-0.7	―	―	―
Aug 06, 2025	2025 (Q2)	-0.31 / -0.14	-0.91	84.62% (+0.77)	―
May 01, 2025	2025 (Q1)	-0.57 / -0.47	-1.76	73.30% (+1.29)	―
Feb 20, 2025	2024 (Q4)	-0.56 / -0.73	-1.18	38.14% (+0.45)	―
Oct 31, 2024	2024 (Q3)	-0.67 / -0.70	1.97	-135.53% (-2.67)	―
Aug 01, 2024	2024 (Q2)	-0.79 / -0.91	-1.13	19.47% (+0.22)	―
May 06, 2024	2024 (Q1)	-0.96 / -1.76	-1.27	-38.58% (-0.49)	―
Feb 15, 2024	2023 (Q4)	-1.16 / -1.18	-1.03	-14.56% (-0.15)	―
Nov 07, 2023	2023 (Q3)	-1.06 / 1.97	-1.09	280.73% (+3.06)	―
Aug 03, 2023	2023 (Q2)	-1.09 / -1.13	-1.05	-7.62% (-0.08)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TVTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$17.24	$16.91	-1.91%
May 01, 2025	$20.76	$21.15	+1.88%
Feb 20, 2025	$23.58	$21.98	-6.79%
Oct 31, 2024	$17.76	$17.50	-1.46%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Travere Therapeutics (TVTX) report earnings?

Travere Therapeutics (TVTX) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Travere Therapeutics (TVTX) earnings time?

Travere Therapeutics (TVTX) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TVTX EPS forecast?

TVTX EPS forecast for the fiscal quarter 2025 (Q3) is -0.27.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing